SBIR/STTR Research Award
Development of 4-Chlorokynurenine to Treat Epilepsy
Award amount
$380,752Program and phase
SBIR · Phase IAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VISTAGEN THERAPEUTICS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- FVFWA5XQJ3V5
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Epilepsy affects over 2.5 million people in the US, and over 180,000 new cases of the disease are diagnosed each year. Nearly half of the people suffering from epilepsy are not effectively treated. Moreover, currentl
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Clinical Development of 4-Cl-KYN to Treat Pain
- Preclinical Development of 4-CI-KYN to Treat Pain
- MULTIVARIATE ANALYSIS FOR MOLECULAR TOXICOLOGY SCREENING
- DEVELOPMET OF STEM CELL TECHNOLOGIES FOR TOXICOLOGY
- IN VITRO STEM CELL ASSAY FOR DRUG TOXICOLOGY ASSESSMENT
Research funding history
8 SBIR/STTR records share this UEI (2000–2009). Reported award amounts total $7,207,962. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services